
Roche Itovebi recommended by CHMP for EU approval for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer
Basel: Roche has announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Itovebi (inavolisib), in combination with palbociclib (Ibrance) and fulvestrant, for the treatment …